Several studies demonstrated that the combination of clinical indicators such as ALP, CEA, and CA19-9 showed better diagnostic results than using a biochemical marker alone to detect BM in patients with GC (WANG and QIN, 2020). This evidence concerns the gene CEACAM5 and gastric cancer.